Interactive Interpreter

HAM-A: Hamilton Anxiety Rating Scale

The HAM-A (Hamilton Anxiety Rating Scale) is a 14-item clinician-rated scale that measures the severity of anxiety symptoms across psychic and somatic subscales. Criterion standard for clinical trials.

For professional reference, research, and education only. Not for diagnosis or medical advice.

HAM-A Score Interpreter

  • HAM-A Score Calculator

    Enter each of the 14 item ratings (0–4) to total them; the range shows below.

    0 of 14 items entered — 14 still blank. The total can only rise, so treat the range as provisional.

    Item 1
    Item 2
    Item 3
    Item 4
    Item 5
    Item 6
    Item 7
    Item 8
    Item 9
    Item 10
    Item 11
    Item 12
    Item 13
    Item 14

    Each item scores 0–4. Items are numbered, not reproduced — enter them from the form in front of you.

  • Enter a total score to see its range.

  • 14 items, each scored 0–4. Total = sum of all items (0–56). Higher scores indicate greater severity.

    Total scoreInterpretation
    24+Severe anxietySignificant impairment across multiple domains; warrants close clinical attention.
    15–23Moderate anxietyLikely functional impairment; treatment response monitoring recommended.
    8–14Mild anxietyClinically significant but limited functional impact; monitor closely.
    0–7Minimal / no anxietyScores ≤7 indicate no clinically significant anxiety.

    Hamilton M (1959); severity ranges per Matza LS et al., Int J Methods Psychiatr Res. 2010;19(4):223-32. Use with caution and validated clinical judgment.

The HAM-A (Hamilton Anxiety Rating Scale) is a 14-item clinician-rated scale for measuring the severity of anxiety symptoms, developed by Max Hamilton in 1959 [1]. It is a long-standing benchmark measure in anxiety treatment research.

What does the HAM-A measure?

The HAM-A is a 14-item clinician-administered rating scale developed to quantify anxiety symptom severity [1]. It remains one of the most widely used observer-rated anxiety scales in pharmacological clinical trials and is a benchmark comparator for evaluating anxiolytic treatments.

Each of the 14 items represents a cluster of symptoms and is scored on a 5-point scale (0 = not present, 4 = very severe), giving totals from 0 to 56. The scale covers two dimensions:

  • Psychic anxiety: mental and cognitive symptoms, items 1–6 and 14.
  • Somatic anxiety: physical symptoms, items 7–13.

This makes it useful for distinguishing between the two anxiety dimensions in clinical research. Its severity ranges were set in a sample with generalized anxiety disorder (GAD) [2], and it is also used in panic disorder, social anxiety and mixed anxiety-depression presentations.

How do you give the HAM-A?

The HAM-A is designed for clinician administration. Each item requires clinical judgment based on both the client's verbal report and direct behavioural observation during the interview. It is intended for use in educational, training, and outcome-tracking contexts by licensed clinicians.

Rate each symptom cluster based on the client's report and your clinical observation over the past week. Score each item 0–4.

Administration takes 10 to 15 minutes of clinician time. For trained clinician use. Scores require clinical context and professional judgment.

A structured interview guide (the SIGH-A) adds administration instructions and clear anchor points; it gave similar but consistently higher scores (by 4.2 points) than the traditional format, and is an acceptable alternative where extensive rater training is not practical [6].

How do you score and interpret the HAM-A?

Each item is scored 0–4: 0 = not present, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. The total is the sum of all 14 items (range 0–56).

Totals run from 0 to 56: 0–7 no or minimal anxiety, 8–14 mild, 15–23 moderate and 24 or above severe [2].

These ranges were derived in a four-week GAD treatment trial (144 adults) from literature review, expert input and MANOVA models, and closely matched clinicians' CGI-S ratings. The authors advise using them with caution until they are validated in larger samples [2]. The scorer at the top of this page shows each range with its note.

Treatment response is traditionally defined as a 50% reduction in the total score; a comparison of HAM-A scores with clinician CGI ratings in escitalopram trials suggests that definition may be too conservative [7].

Psychic anxiety subscale

Items 1–6 and 14 (anxious mood, tension, fears, insomnia, intellectual, depressed mood, behaviour at interview). Max = 28.

Reflects cognitive, emotional, and behavioural manifestations of anxiety.

Somatic anxiety subscale

Items 7–13 (muscular, sensory, cardiovascular, respiratory, GI, GU, autonomic). Max = 28.

Reflects physical and autonomic symptoms of anxiety. Particularly useful in differentiating anxiety from depression.

HAM-A items and scoring anchors

Each item covers a symptom cluster. Score based on the most prominent symptom within each cluster over the past week.

#ItemSubscaleKey symptom clusters
1Anxious moodPsychicWorry, anticipation of the worst, fearful anticipation, irritability
2TensionPsychicFeelings of tension, fatigue, startle response, inability to relax, tearfulness, trembling
3FearsPsychicFear of dark, strangers, being left alone, animals, traffic, crowds
4InsomniaPsychicDifficulty falling asleep, broken sleep, unsatisfying sleep, dreams, nightmares
5Intellectual (cognitive)PsychicDifficulty concentrating, poor memory
6Depressed moodPsychicLoss of interest, lack of pleasure in hobbies, depression, early waking, diurnal mood swing
7Somatic (muscular)SomaticMuscular pains, aches, stiffness, twitching, grinding of teeth, unsteady voice, increased muscular tone
8Somatic (sensory)SomaticTinnitus, blurring of vision, hot/cold flushes, feelings of weakness, prickling sensation
9Cardiovascular symptomsSomaticTachycardia, palpitations, pain in chest, throbbing of vessels, faintness, skipped beat
10Respiratory symptomsSomaticPressure or constriction in chest, choking feelings, sighing, dyspnea
11Gastrointestinal symptomsSomaticDifficulty swallowing, flatulence, dyspepsia, borborygmi, nausea, vomiting, looseness of bowels, loss of weight
12Genitourinary symptomsSomaticFrequency of micturition, urgency, amenorrhea, menorrhagia, frigidity, premature ejaculation
13Autonomic symptomsSomaticDry mouth, flushing, pallor, sweating, giddiness, tension headache
14Behaviour at interviewPsychicFidgeting, restlessness, tremor, furrowed brow, strained face, sighing, rapid breathing

Psychometric properties

Reliability

  • Inter-rater and test-retest. In 89 participants across three anxiety research sites, both the traditional HAM-A and the structured interview version showed high inter-rater and test-retest reliability [6].
  • Rating consistency in trials. An expert working group applied consistency checks to 40,349 HAM-A administrations from 15 clinical trials: 35% had at least one flag of any type, and 20% had at least one logical scoring inconsistency. Rater training and structured administration help keep measurement reliable [4].

Factor structure

In 88 African American adults with co-occurring trauma symptoms and heavy alcohol use, a two-factor (psychic and somatic) solution fit the data adequately, similar to earlier reports in largely White samples. The total score, but not the subscales, predicted PTSD severity, a sign that the subscales perform less well when used on their own [5].

Responsiveness

A 50% reduction in total score from baseline is the traditional responder definition [7]. The HAM-A has been a primary or secondary efficacy endpoint in trials of SSRIs, SNRIs, and benzodiazepines, so its scores can be compared across many studies.

HAM-A vs GAD-7: choosing the right tool

The HAM-A and GAD-7 serve complementary rather than competing roles in clinical practice. Choosing between them depends on the clinical context, available time, and the specific information needed.

FeatureHAM-AGAD-7
FormatClinician-administered interviewClient self-report
Items147
Completion time10–15 minutes (clinician)2–3 minutes (client)
SubscalesPsychic anxiety + somatic anxietyNone (total score only)
Score range0–560–21
Primary useClinical research endpoint; detailed severity trackingScreening; routine outcome monitoring
Sensitivity for GADHigh (clinician judgment)89% at optimal cut-point [3]
Requires clinician timeYesNo
LicencePublic domain (listed by the US National Institutes of Health)Pfizer states no permission is required to reproduce, translate, display or distribute it

The GAD-7 is generally the preferred choice for large-scale screening, routine outcome monitoring in primary care, and high-volume settings where clinician-administered interviews are not practical. It identifies probable GAD cases efficiently and was validated in a large primary care sample [3].

The HAM-A is the better choice when:

  • clinician judgment is needed to separate somatic symptoms of anxiety from those with a medical origin;
  • psychic versus somatic anxiety profiles are clinically meaningful (for example, differentiating medication response patterns);
  • a widely benchmarked outcome measure is required for research.

Its long track record in pharmacological trials gives HAM-A scores context for treatment effect comparisons that newer scales lack.

In measurement-based care settings, both measures can be used together: the GAD-7 at each visit for rapid tracking, with the HAM-A reserved for baseline assessment, complex presentations, or clinical trial protocols.

Limitations

  • Provisional severity ranges. The severity bands were derived in a single GAD trial sample of 144 adults, and the authors state the cutoffs should be used with caution and validated in larger samples [2].
  • Rater dependence. Scores rely on clinician judgment; in 40,349 trial administrations, 35% raised at least one consistency flag, so rater training and structured interview guides matter [4].
  • Overlap with depression. Items such as depressed mood and insomnia overlap with depression measures, so HAM-A totals are not specific to anxiety.
  • Somatic items. Physical symptoms can stem from medical illness or medication, which may inflate somatic subscale scores.
  • Not a diagnosis. The HAM-A rates severity; it does not establish an anxiety disorder diagnosis.

GAD-7: 7-item self-report anxiety scale. Faster screening alternative to HAM-A for routine outcome monitoring and large-scale screening.

HAM-D (Hamilton Depression Rating Scale): clinician-administered depression severity scale. Often co-administered with HAM-A in mixed anxiety-depression presentations to profile symptom dimensions separately.

DASS-21 (Depression Anxiety Stress Scales): 21-item self-report scale measuring depression, anxiety, and stress. Complements HAM-A for broader symptom profiling in research contexts.

For individuals: This page is a clinical reference, not a diagnostic tool. If you have concerns about your own symptoms, bring this information to a qualified mental health professional.

FAQ

  • What is the HAM-A?

    The Hamilton Anxiety Rating Scale (HAM-A) is a 14-item clinician-administered scale developed by Max Hamilton in 1959 to quantify anxiety symptom severity. It remains one of the most widely used observer-rated anxiety scales in pharmacological clinical trials and is considered the benchmark for evaluating anxiolytic treatments.

  • How are HAM-A scores interpreted?

    HAM-A scores range from 0 to 56. A score of 7 or below indicates no or minimal anxiety; 8–14 mild anxiety; 15–23 moderate anxiety; and 24 or above indicates severe anxiety. These ranges were set in a 2010 study of 144 adults with generalized anxiety disorder and closely matched clinicians' CGI-S ratings; its authors advise caution until they are validated in larger samples. Treatment response is traditionally defined as a 50 per cent or greater reduction in score.

  • How does the HAM-A differ from self-report scales like the GAD-7?

    The HAM-A is administered by a trained clinician through a structured interview, while the GAD-7 is completed by the client without a clinician. The HAM-A captures both observable signs and subjective reports and provides separate subscale scores for psychic anxiety and somatic anxiety. The GAD-7 is faster and better suited for screening and routine monitoring. The HAM-A is preferred when somatic versus psychic anxiety distinction matters clinically or when a rigorous endpoint is needed for research.

  • Why is the HAM-A used in clinical trials?

    The HAM-A has been a primary or secondary efficacy endpoint in many clinical trials evaluating anxiolytic medications, including SSRIs, SNRIs, and benzodiazepines. Its clinician-rated format reduces response bias, and its psychic and somatic subscales allow for differentiation of anxiety symptom profiles. Its long use gives a large body of trial data for cross-study comparisons.

We help connect the dots, sooner

Learn more

HiBoop does not offer this scale. This page is reference material.This library is an academic and clinical reference. A scale described here is not necessarily offered in HiBoop; each page says whether it is.